The 36-month beta value for IOVA is at 0.56. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for IOVA is 247.05M, and currently, shorts hold a 23.04% of that float. The average trading volume for IOVA on December 23, 2024 was 6.18M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IOVA) stock’s latest price update
The stock of Iovance Biotherapeutics Inc (NASDAQ: IOVA) has increased by 1.29 when compared to last closing price of 7.38.Despite this, the company has seen a loss of -4.66% in its stock price over the last five trading days. globenewswire.com reported 2024-12-20 that SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance’s common stock to forty-eight new, non-executive employees.
IOVA’s Market Performance
IOVA’s stock has fallen by -4.66% in the past week, with a monthly drop of -9.28% and a quarterly drop of -19.97%. The volatility ratio for the week is 5.65% while the volatility levels for the last 30 days are 5.26% for Iovance Biotherapeutics Inc The simple moving average for the last 20 days is -11.03% for IOVA’s stock, with a simple moving average of -26.76% for the last 200 days.
Analysts’ Opinion of IOVA
Many brokerage firms have already submitted their reports for IOVA stocks, with UBS repeating the rating for IOVA by listing it as a “Buy.” The predicted price for IOVA in the upcoming period, according to UBS is $17 based on the research report published on October 24, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see IOVA reach a price target of $10, previously predicting the price at $19. The rating they have provided for IOVA stocks is “Neutral” according to the report published on July 29th, 2024.
Goldman gave a rating of “Buy” to IOVA, setting the target price at $12 in the report published on November 20th of the previous year.
IOVA Trading at -20.20% from the 50-Day Moving Average
After a stumble in the market that brought IOVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.22% of loss for the given period.
Volatility was left at 5.26%, however, over the last 30 days, the volatility rate increased by 5.65%, as shares sank -12.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.20% lower at present.
During the last 5 trading sessions, IOVA fell by -4.59%, which changed the moving average for the period of 200-days by -52.36% in comparison to the 20-day moving average, which settled at $8.40. In addition, Iovance Biotherapeutics Inc saw -8.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IOVA starting from Maynard Ryan D, who sale 50,000 shares at the price of $10.06 back on Nov 12 ’24. After this action, Maynard Ryan D now owns 7,500 shares of Iovance Biotherapeutics Inc, valued at $503,000 using the latest closing price.
Maynard Ryan D, the Director of Iovance Biotherapeutics Inc, proposed sale 50,000 shares at $10.06 during a trade that took place back on Nov 12 ’24, which means that Maynard Ryan D is holding shares at $503,104 based on the most recent closing price.
Stock Fundamentals for IOVA
Current profitability levels for the company are sitting at:
- -4.73 for the present operating margin
- -0.14 for the gross margin
The net margin for Iovance Biotherapeutics Inc stands at -4.51. The total capital return value is set at -0.49. Equity return is now at value -56.65, with -44.48 for asset returns.
Based on Iovance Biotherapeutics Inc (IOVA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -363.65. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -123.34.
Currently, EBITDA for the company is -427.43 million with net debt to EBITDA at 0.22. When we switch over and look at the enterprise to sales, we see a ratio of 24.07. The receivables turnover for the company is 1.63for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.22.
Conclusion
In conclusion, Iovance Biotherapeutics Inc (IOVA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
